|
US6402215B1
(en)
*
|
1996-05-21 |
2002-06-11 |
American Moto Products, Inc. |
Vehicle cargo bed extender
|
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
US7977345B2
(en)
|
2004-07-02 |
2011-07-12 |
Exelixis, Inc. |
c-MET modulators and method of use
|
|
EP1874759A4
(en)
|
2005-04-06 |
2009-07-15 |
Exelixis Inc |
C-MET MODULATORS MODULATORS AND METHODS OF USE
|
|
PL2101759T3
(pl)
|
2006-12-14 |
2019-05-31 |
Exelixis Inc |
Sposoby stosowania inhibitorów MEK
|
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
|
AR075084A1
(es)
|
2008-09-26 |
2011-03-09 |
Smithkline Beecham Corp |
Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
|
|
JP5486606B2
(ja)
|
2008-11-13 |
2014-05-07 |
エクセリクシス， インク． |
キノリン誘導体の調製方法
|
|
US20130030172A1
(en)
|
2008-12-04 |
2013-01-31 |
Exelixis, Inc. |
Methods of Preparing Quinoline Derivatives
|
|
NZ779754A
(en)
|
2009-01-16 |
2023-04-28 |
Exelixis Inc |
Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
CN102510855B
(zh)
|
2009-07-17 |
2015-11-25 |
埃克塞里艾克西斯公司 |
N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
MX2012008898A
(es)
*
|
2010-02-03 |
2012-11-06 |
Incyte Corp |
Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
|
|
AU2011224203A1
(en)
|
2010-03-12 |
2012-10-04 |
Exelixis, Inc |
Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin -4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl] -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US20120070368A1
(en)
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
|
EA030435B1
(ru)
|
2010-07-16 |
2018-08-31 |
Экселиксис, Инк. |
ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
|
|
US20140186407A9
(en)
|
2010-07-16 |
2014-07-03 |
Exelixis Inc. |
C-Met Modulator Pharmaceutical Compositions
|
|
US20140057908A1
(en)
|
2010-09-27 |
2014-02-27 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
JP2013540759A
(ja)
|
2010-09-27 |
2013-11-07 |
エクセリクシス， インク． |
去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
|
|
MX352926B
(es)
|
2010-09-27 |
2017-12-14 |
Exelixis Inc |
Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
|
|
WO2012064967A2
(en)
*
|
2010-11-10 |
2012-05-18 |
Cedars-Sinai Medical Center |
Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
|
|
WO2012071321A1
(en)
|
2010-11-22 |
2012-05-31 |
Glaxosmithkline Llc |
Method of treating cancer
|
|
BR112013020362A2
(pt)
|
2011-02-10 |
2018-05-29 |
Exelixis Inc |
processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
MX2013012695A
(es)
|
2011-05-02 |
2014-03-27 |
Exelixis Inc |
Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
|
|
TW201306842A
(zh)
|
2011-06-15 |
2013-02-16 |
Exelixis Inc |
使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
|
|
EP2758057B1
(en)
|
2011-09-22 |
2017-05-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
|
CN104395284A
(zh)
|
2011-10-20 |
2015-03-04 |
埃克塞里艾克西斯公司 |
制备喹啉衍生物的方法
|
|
IN2014CN04067A
(enExample)
|
2011-11-08 |
2015-10-23 |
Exelixis Inc |
|
|
JP2015508066A
(ja)
*
|
2012-02-06 |
2015-03-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｅｍｐ２は、ｖｅｇｆの誘導を通じた癌細胞における血管形成を制御する
|
|
CN103304552B
(zh)
*
|
2012-03-09 |
2016-12-28 |
广东东阳光药业有限公司 |
取代的吡啶化合物及其使用方法和用途
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
JP6513567B2
(ja)
|
2012-09-07 |
2019-05-15 |
エクセリクシス， インク． |
肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
|
|
US20140221372A1
(en)
|
2013-02-06 |
2014-08-07 |
GlaxoSmithKline Intellectual Property (NO 2.) Limited |
Method of administration and treatment
|
|
CA2907334C
(en)
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
WO2014165779A1
(en)
|
2013-04-04 |
2014-10-09 |
Exelixis, Inc. |
Drug combinations to treat cancer
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
BR112016018450A2
(pt)
|
2014-02-14 |
2018-09-18 |
Exelixis Inc |
formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
|
|
EP3119476A1
(en)
|
2014-03-17 |
2017-01-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
UA121655C2
(uk)
|
2014-04-25 |
2020-07-10 |
Екселіксіс, Інк. |
Спосіб лікування аденокарциноми легень
|
|
EP3174854B1
(en)
|
2014-07-31 |
2022-08-24 |
Exelixis, Inc. |
Method of preparing fluorine-18 labeled cabozantinib and its analogs
|
|
MX382904B
(es)
|
2014-08-05 |
2025-03-13 |
Exelixis Inc |
Combinaciones de fármacos para tratar mieloma múltiple.
|
|
TW201625243A
(zh)
|
2014-10-14 |
2016-07-16 |
艾克塞里克斯公司 |
用於治療黑素瘤之藥物組合
|